Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Phio Pharmaceuticals Corp (NQ: PHIO )

3.120 +0.140 (+4.70%)
Streaming Delayed Price Updated: 3:59 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,467
Open 2.980
Bid (Size) 3.000 (1)
Ask (Size) 3.210 (2)
Prev. Close 2.980
Today's Range 2.946 - 3.200
52wk Range 2.400 - 18.81
Shares Outstanding 860,721
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Marlborough Massachusetts--(Newsfile Corp. - November 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new... 
Via Newsfile
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Marlborough, Massachusetts--(Newsfile Corp. - October 24, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary... 
Via Newsfile

Performance

YTD
-54.96%
-54.96%
1 Month
-1.89%
-1.89%
3 Month
+6.74%
+6.74%
6 Month
-57.71%
-57.71%
1 Year
-72.22%
-72.22%

More News

Read More
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Via Newsfile
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series
Via Newsfile
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference
Via Newsfile
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells
Via Newsfile
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Via Newsfile
Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference
Via Newsfile
INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society
Via Newsfile
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Via Newsfile
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA
Via Newsfile
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Via Newsfile
PHIO Stock Earnings: Phio Pharma Misses EPS for Q2 2024
Via InvestorPlace
Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Via Newsfile
Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Phio Pharmaceuticals Announces New Chief Financial Officer
Via Newsfile
Topics Initial Public Offering
Exposures Securities Market
Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
Via Newsfile
Topics Regulatory Compliance
Exposures Legal Regulatory
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
Via Newsfile
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.